2nd How I Manage CAR-T Therapies and Bispecific Antibodies for my Patients
September 29-October 1, 2023 – Berlin, Germany
Chairs: Ulrich Jäger (Vienna), Marie José Kersten (Amsterdam), Loretta Nastoupil (Houston)

Friday, September 29, 2023

08:30-08:40	**Welcome**	Conference Chairpersons
08:40-09:05	**Keynote lecture** **Chair: Marie José Kersten (Amsterdam)**	
08:40-09:00	CAR T-cell therapy: something old, something new (novel targets/tandem CARs)	Jeremy Abramson (Boston)
09:00-09:05	Discussion	
	SESSION I – Non-hodgkin lymphoma (NHL) **Chairs: Loretta Nastoupil (Houston), Jeremy Abramson (Boston)**	
09:05-09:12	Interactive case Diffuse large B-cell lymphoma and radiotherapy	Tom van Meerten (Groningen)
09:12-09:15	*Discussion*	
09:15-09:35	Case-based lecture CAR-T: patient selection and bridging strategies	Catherine Thieblemont (Paris)
09:35-09:40	*Discussion*	
09:40-10:00	Case-based lecture Bispecific antibodies	Martin Hutchings (Copenhagen)
10:00-10:05	*Discussion*	
10:05-10:25	Case-based lecture Alternative cell sources: alloCAR-T, iPSC, NK CAR	Stephan Fricke (Leipzig)
10:25-10:30	*Discussion*	
10:30-10:37	Interactive case Follow-up of patients after successful treatment	Pere Barba (Barcelona)
10:37-10:40	*Discussion*	
10:40-10:45	Brief oral communication A novel anti-CD117 Bispecific T cell engager for rapid and efficient hematopoietic stem cell depletion and safe bone marrow conditioning	Giada Dal Collo (Rotterdam)
10:45-10:48	*Discussion*	
10:48-11:10	*Panel discussion*	

11:10-11:40 Coffee Break

SESSION II – Multiple myeloma (MM)
Chair: Ulrich Jäger (Vienna)

11:40-11:47	Interactive case CAR-T and infections in multiple myeloma	Kai Rejeski (Munich)
11:47-11:50	*Discussion*	
11:50-12:10	Case-based lecture CAR in multiple myeloma	Maria-Victoria Mateos (Salamanca)
12:10-12:40	Case-based lecture Bispecifics and sequencing in multiple myeloma	Monique Minnema (Utrecht)
12:40-12:50	*Discussion*	
12:50-12:57	Interactive case Clinical study opportunities for patients	Johannes Waldschmidt (Würzburg)
12:57-13:00	*Discussion*	
13:00-13:05	Brief oral communication Artificial Intelligence-assisted development of high affinity anti-CD79b CAR-T cells for the treatment of relapsed/ refractory B-Non Hodgkin Lymphomas and Multiple Myeloma	Vincenzo Perriello (Perugia)
13:05-13:08	*Discussion*	
13:08-13:30	*Panel discussion*	

13:30-15:00 Lunch

SESSION III – Novel indications CAR T-cell therapy
Chairs: Catherine Thieblemont (Paris), Marie José Kersten (Amsterdam)

15:00-15:07	Interactive case Pediatric acute lymphoblastic leukaemia	André Baruchel (Paris)
15:07-15:10	*Discussion*	
15:10-15:30	Case-based Lecture Adult acute lymphoblastic leukaemia	Claire Roddie (London)
15:30-15:35	*Discussion*	
15:35-15:55	Case-based lecture Mantle cell lymphoma	Marie José Kersten (Amsterdam)
15:55-16:00	*Discussion*	
16:00-16:20	Case-based lecture Follicular lymphoma and T-cell lymphoma	Loretta Nastoupil (Houston)
16:20-16:25	*Discussion*	
16:25-16:32	Interactive case T-cell lymphoma	Kate Cwynarski (London)
16:32-16:35	*Discussion*	

16:35-16:40	Brief oral communication Epcoritamab SC + R2 in patients with relapsed or refractory follicular lymphoma yields high response rates regardless of POD24 status: updated results from EPCORE NHL-2	Anna Sureda (Barcelona)
16:40-16:43	*Discussion*	
16:43-17:05	*Panel*	
17:05-17:35	***Coffee break***	

17:35-18:15 DEBATE 1 – CAR-T in 2nd line diffuse large B-cell lymphoma (DLBCL)
Chair: Jeremy Abramson (Boston)

Audience votes

17:35-17:50	Pro	Frederick Locke (Tampa)
17:50-18:05	Con	Anna Sureda (Barcelona)
18:05-18:15	*Discussion*	

Audience votes again

18:15-19:05 ROUNDTABLE 1 – Affordability and access to CAR-T cell and bispecific antibody treatment
Chair: Kate Cwynarski (London)

18:15-18:20	Future projections	Frederick Thielen (Rotterdam)
18:20-18:25	Patient survey	Natacha Bolanos (Madrid)
18:25-18:30	Mapping project of access to CAR T-cell therapies in Europe	Elise Pennings (Amsterdam)
18:30-18:35	Access in different ethnic groups	Loretta Nastoupil (Houston)
18:35-19:05	*Discussion*	Ulrich Jäger (Vienna) all Roundtable 1 chair & speakers

19:15-20:30 ***Poster Walks and Welcome get-together buffet dinner for all***
Poster Walk leaders: Jordan Gauthier (Seattle) & Kate Cwynarski (London)

Saturday, September 30, 2023

08:30-09:30 3 Simultaneous Meet the Expert sessions

1.	Point of care production	Alvaro Urbano-Ispizua (Barcelona) Claire Roddie (London)
2.	NK CARs	Veronika Bachanova (Minneapolis)
3.	Immune escape from CAR-T in multiple myeloma	Johannes Waldschmidt (Würzburg)

09:40-10:40 **SATELLITE SYMPOSIUM**

Bispecific antibodies in DLBCL: present and future prospects

Speakers: Bertram Glass (Berlin), Chris Fox (Nottingham), Pablo Umana (Zurich)

This symposium is organized and sponsored by Roche

10:40-11:10 Coffee Break

SESSION IV – Managing toxicity of CAR-T and bispecific antibody treatment
Chair: Claire Roddie (London)

11:10-11:17	Interactive case Prediction of toxicity in CARs and bispecifics	Anna Sureda (Barcelona)
11:17-11:20	*Discussion*	
11:20-11:40	Case-based lecture Humanized mouse models for efficacy and toxicity profiling after CAR-T cell therapy	Monica Casucci (Milan)
11:40-11:45	*Discussion*	
11:45-12:05	Case-based lecture Immune effector cell associated neurological syndrome: neurotoxicity and long-term symptoms	Frederick Locke (Tampa)
12:05-12:10	*Discussion*	
12:10-12:30	Case-based lecture Cytopenias and infections	Kai Rejeski (Munich)
12:30-12:35	*Discussion*	
12:35-12:42	Interactive case EBMT recommendations	Claire Roddie (London)
12:42-12:45	*Discussion*	
12:45-12:50	Brief oral communication Severe immune effector cell associated MAS/HLH-like syndrome: If you know it, you will recognize it	Alex Moretti (Monza)
12:50-12:53	*Discussion*	
12:53-13:15	*Panel discussion*	

13:15-14:50 Lunch

14:50-15:35 ROUNDTABLE 2 – Ethical issues in CAR T-cell treatment
Chair: Anna Sureda (Barcelona)

14:50-14:55	Eligibility and rapid progression	Marie José Kersten (Amsterdam)
14:55-15:00	Patient perspective	Hans Scheurer (Amsterdam)
15:00-15:05	Patient's view of CAR T-cell therapy	Jonathan Clark (Loosdrecht)
15:05-15:35	*Discussion*	Jeremy Abramson (Boston) all Roundtable 2 chair & speakers

15:35-16:15 DEBATE 2 – CAR-T vs bispecific antibody
Chair: Ulrich Jäger (Vienna)

Audience votes

15:35-15:50	Pro CAR-T	Jeremy Abramson (Boston)
15:50-16:05	Pro bispecific antibody	Elizabeth Budde (Duarte)
16:05-16:15	*Discussion*	

Audience votes again

16:15-16:45 Coffee break

SESSION V- Real world data CAR-T
Chair: Pere Barba (Barcelona)

16:45-16:52	Interactive case Mantle cell lymphoma	Gloria Iacoboni (Barcelona)
16:52-16:55	*Discussion*	
16:55-17:15	Case-based lecture Diffuse large B-cell lymphoma - US experience	Frederick Locke (Tampa)
17:15-17:20	*Discussion*	
17:20-17:40	Case-based lecture Diffuse large B-cell lymphoma - UK experience	Andrea Kuhnl (London)
17:40-17:45	*Discussion*	
17:45-17:52	Interactive case CARs and comorbidities	Jordan Gauthier (Seattle)
17:52-17:55	*Discussion*	
17:55-18:00	Brief oral communication Autologous stem cell transplantation before Lymphocyte apheresis for CAR-T cells therapy negatively impacts on T-cells fitness in DLBCL patients.	Mirko Farina (Brescia)
18:00-18:03	*Discussion*	

18:03-18:25 Panel discussion

Sunday, October 1, 2023

08:30-09:30 3 Simultaneous Meet the Expert Sessions

1. CAR-T in solid tumors — Sebastian Klobuch (Amsterdam)
2. CAR-T in secondary central nervous system lymphoma — Jeremy Abramson (Boston)
3. The role of the microbiome in immunotherapy — Marcel van den Brink (New York)

SESSION VI – Life after CAR T-cell therapy
Chair: Tom van Meerten (Groningen)

09:40-09:47	Interactive case Relapse in multiple myeloma after CAR-T	Lukas Scheller (Würzburg)
09:47-09:50	*Discussion*	
09:50-10:10	Case-based lecture CAR-T resistance mechanisms	Michael Green (Houston)
10:10-10:15	*Discussion*	
10:15-10:35	Case-based lecture Treatment after CAR-T failure in diffuse large B-cell lymphoma: bispecific antibody	Elizabeth Budde (Duarte)
10:35-10:40	*Discussion*	
10:40-11:00	Case-based lecture Second CAR-T infusion (diffuse large B-cell lymphoma, follicular lymphoma, bridge to allo?)	Jordan Gauthier (Seattle)
11:00-11:05	*Discussion*	
11:05-11:12	Interactive case Allo after CAR-T	Anna Sureda (Barcelona)
11:12-11:15	*Discussion*	
11:15-11:20	Brief oral communication Side-effect incidence in patients with relapsed Large B-cell lymphomas who have received CAR-T v other therapies – an analysis of patient reported outcomes from the Lymphoma Coalition's Global Patient Survey.	Natacha Bolanos (Madrid)
11:20-11:23	*Discussion*	
11:23- 11:45	*Panel discussion*	
11:45-12:10	**Keynote lecture** **Chair: Loretta Nastoupil (Houston)**	
11:45-12:05	Cellular therapy in 2030	Catherine Bollard (Washington)
12:05-12:10	Discussion	
12:10-12:20	***Closing remarks***	Conference Chairpersons

MEETING CLOSURE